158 related articles for article (PubMed ID: 18021334)
21. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia.
Plard C; Bressolle F; Fakhoury M; Zhang D; Yacouben K; Rieutord A; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2007 Sep; 60(4):609-20. PubMed ID: 17195068
[TBL] [Abstract][Full Text] [Related]
22. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2004 Apr; 31(4):645-8. PubMed ID: 15088287
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma].
Fernández Megía MJ; Alós Almiñana M; Esquer Borrás J
Farm Hosp; 2004; 28(6):433-9. PubMed ID: 15628946
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications].
Bannwarth B; Péhourcq F; Lequen L
Therapie; 1997; 52(2):129-32. PubMed ID: 9231507
[TBL] [Abstract][Full Text] [Related]
25. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.
Ng CM; Bruno R; Combs D; Davies B
J Clin Pharmacol; 2005 Jul; 45(7):792-801. PubMed ID: 15951469
[TBL] [Abstract][Full Text] [Related]
27. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients.
Bressolle F; Bologna C; Kinowski JM; Arcos B; Sany J; Combe B
J Rheumatol; 1997 Oct; 24(10):1903-9. PubMed ID: 9330930
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
31. Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis.
Gumbhir-Shah K; Cevallos WH; DeCleene SA; Korth-Bradley JM
J Rheumatol; 1996 Jun; 23(6):984-9. PubMed ID: 8782127
[TBL] [Abstract][Full Text] [Related]
32. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.
Godfrey C; Sweeney K; Miller K; Hamilton R; Kremer J
Br J Clin Pharmacol; 1998 Oct; 46(4):369-76. PubMed ID: 9803986
[TBL] [Abstract][Full Text] [Related]
33. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg.
Kremer JM; Hamilton RA
J Rheumatol; 1995 Nov; 22(11):2072-7. PubMed ID: 8596147
[TBL] [Abstract][Full Text] [Related]
34. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of the novel anticancer agent KRN7000.
Crul M; Mathôt RA; Giaccone G; Punt CA; Rosing H; Hillebrand MX; Ando Y; Nishi N; Tanaka H; Schellens JM; Beijnen JH
Cancer Chemother Pharmacol; 2002 Apr; 49(4):287-93. PubMed ID: 11914907
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants.
Yukawa E; Suematsu F; Yukawa M; Minemoto M
J Clin Pharm Ther; 2005 Apr; 30(2):159-63. PubMed ID: 15811169
[TBL] [Abstract][Full Text] [Related]
37. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation.
Conil JM; Georges B; Lavit M; Laguerre J; Samii K; Houin G; Saivin S
Br J Clin Pharmacol; 2007 Jul; 64(1):27-35. PubMed ID: 17324245
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data.
Vucićević K; Miljković B; Velicković R; Pokrajac M; Mrhar A; Grabnar I
Ther Drug Monit; 2007 Dec; 29(6):781-8. PubMed ID: 18043476
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of adefovir dipivoxil tablets in healthy Chinese volunteers.
Huang J; Zhang Y; Huang X; Li L; Li Y; Wang K; Yang J; He Y; Lv Y; Zheng Q
Int J Clin Pharmacol Ther; 2014 Jan; 52(1):8-14. PubMed ID: 24219967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
